Actively Recruiting
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
Led by Shanghai 6th People's Hospital · Updated on 2024-09-19
20
Participants Needed
1
Research Sites
194 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.
CONDITIONS
Official Title
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Confirmed colorectal cancer with liver metastases not suitable for surgery or refusing surgery
- No serious complications like bleeding or blockage if primary tumor is unresectable or recurrent
- Disease progression or new liver metastases after first-line treatment failure
- No more than 5 liver lesions, each 3 cm or smaller in diameter
- At least 1 month since last chemotherapy, radiotherapy, or local liver treatment if previously treated
- Liver function Child-Pugh class A or B; bilirubin ≤ 3.0 mg/dL; creatinine ≤ 2.5 mg/dL; white blood cells ≥ 2.0 x10^9/L; platelets ≥ 100 x10^9/L
- Eastern Cooperative Oncology Group performance status 0 to 2
- Willing to receive anti-PD-1 monoclonal antibody therapy
You will not qualify if you...
- Liver function Child-Pugh class C
- Expected survival less than 3 months
- Major organ failure or insufficiency
- Active infections
- Irreversible blood clotting problems
- Refractory large ascites, pleural effusion, or severe weight loss (cachexia)
- Unable to cooperate with treatment
- Any other condition that the investigator believes makes participation unsuitable or unsafe
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Sixth People's Hospital
Shanghai, China
Actively Recruiting
Research Team
C
Chief physician of Medical Oncology
CONTACT
C
Chief physician of Medical Oncology
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here